Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» ICER
ICER
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
Pharmaforum
ICER
AbbVie
Rinvoq
rheumatoid arthritis
biosimilars
Flag link:
ICER draws new gene therapy pricing framework
ICER draws new gene therapy pricing framework
Biopharma Dive
ICER
gene therapy
Flag link:
U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions
U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions
Forbes
insurers
transparency
formulary
ICER
Flag link:
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
Endpoints
ICER
drug pricing
JNJ
Xarelto
Amarin
Vascepa
Flag link:
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Flag link:
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Humira, Rituxan top list of U.S. drugs with biggest price increases -report
Yahoo/Reuters
ICER
drug pricing
AbbVie
Humira
Roche
Rituxan
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
ICER dings Novo's new oral diabetes drug
ICER dings Novo's new oral diabetes drug
Biopharma Dive
Novo Nordisk
diabetes
ICER
oral semaglutide
Eli Lilly
Boehringer Ingelheim
Jardiance
Ozempic
Flag link:
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
Endpoints
peanut allergy
Aimmune Therapeutics
DBV Technologies
ICER
AR101
Viaskin Peanut
Flag link:
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato
Fierce Pharma
Novartis
Mayzent
JNJ
Spravato
ICER
Flag link:
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER
Endpoints
Duchenne Muscular Dystrophy
ICER
Sarepta Therapeutics
Exondys 51
Flag link:
ICER seeks to make drug price research more accessible
ICER seeks to make drug price research more accessible
Biopharma Dive
ICER
drug pricing
Flag link:
ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’
ICER chastises J&J for overpricing depression drug esketamine ‘where there is such need for treatment’
Endpoints
JNJ
drug pricing
antidepressants
esketamine
Spravato
ICER
Flag link:
ICER's Growing Impact On Drug Pricing And Reimbursement
ICER's Growing Impact On Drug Pricing And Reimbursement
Forbes
ICER
drug pricing
reimbursement
Flag link:
Should Biogen Investors Be Extra Nervous Right Now?
Should Biogen Investors Be Extra Nervous Right Now?
Motley Fool
Biogen
Alzheimer's disease
ICER
investors
Spinraza
Flag link:
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Fierce Pharma
Novartis
ICER
drug pricing
Zolgensma
gene therapy
spinal muscular atrophy
Flag link:
Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate
Drug-Price Watchdog ICER Dives into Trump-Fueled Pharma Rebate Debate
Xconomy
Donald Trump
ICER
drug pricing
Flag link:
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
Flag link:
The list of shame no biopharma wants to join
The list of shame no biopharma wants to join
EP Vantage
ICER
drug pricing
Flag link:
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
Flag link:
Pages
1
2
next ›
last »